Study of patients who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just the medications.

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and their dependents began using the drugs — and now, they're being told that coverage was accidental.

A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present just as many opportunities as pitfalls. People taking the drugs do indeed eat less—especially indulgent treats.

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims shared with Reuters.

A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like Ozempic.

GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according to a new analysis of U.S. health insurance claims.